Mitochondrial disorders are a heterogeneous and a complex group of neuromuscular disorders resulting from dysfunction of oxidative phosphorylation (OXPHOS). Defects in enzymes encoded by nuclear genes (nDNA) or mitochondrial genome (mtDNA) cause myopathy. The nuclear genome encodes most of the subunits of enzyme complexes, assembly proteins and mtDNA replication, transcription and translation, while, the mitochondrial genome encodes 13subunits of the OXPHOS system, rRNA and tRNA. The cross talk between nDNA and mtDNA is crucial for the cellular regulation of mtDNA integrity, copy number and mitochondrial protein production. POLG1, a nuclear gene essential for mtDNA replication encodes for the catalytic subunit of mitochondrial polymerase gamma. Mutations in POLG1 results in a spectrum of clinical phenotypes. In this study, 910 patients seen between 2002-2017, clinically fulfilling the modified Walkers criteria who underwent skeletal muscle biopsy were analyzed. Long range PCR done on 630/910 cases, revealed multiple deletions in 71. We have sequenced intron-exon boundaries of POLG1 in 351 cases (71 cases with multiple deletions and 280 cases where deletions could not done). Mutations were identified in 18/351(5%) patients. The most common clinical phenotype noted in these 18 cases was CPEO. There were 9 males and 9 females with age at onset ranging from 2 -20 years. Morphologically, muscle biopsy revealed characteristic ragged red fibres with ultrastructural evidence of abnormal mitochondria in 8 cases. Respiratory chain analysis revealed a multiple complex deficiency in 8/18. The reported mutations identified include p.L304R (n=10), p.A682T(n=1), p.R1097G (n=1), p.E1143G (n=1), p.H110Y & p.E1143G (n=1), p.R1187W (n=1), p.R627Q (n=1). In addition, two novel mutations p.Q49H and p.V1106A were noted. In our cohort, a p.L304R mutation was more prevalent and seen in younger age group. Detailed clinical, biochemical, pathological and genetics findings will be presented.